ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aclaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.48+0.20 (+6.10%)
Close on Oct 19, 2026
- Market cap
- $496.72M
- P/E (TTM)
- –
- Dividend yield
- –
Aclaris Therapeutics, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single reportable segment | $1.63M | $2.00M | – | – | $1.78M | $1.46M | – | – | – | – | – | – | 100.0% | -8.3% |
| Contract Research Segment | – | – | – | $485.00K | $442.00K | $445.00K | $615.00K | $645.00K | $625.00K | $657.00K | $4.42M | $4.11M | – | – |
| Therapeutics Segment | – | – | – | $2.81M | $1.34M | $1.01M | $8.60M | $3.70M | $2.14M | $1.74M | $17.00M | $8.58M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single reportable segment | -$24.24M | -$22.19M | – | – | -$18.41M | -$18.08M | – | – | – | – | – | – | +31.7% |
| Contract Research Segment | – | – | – | -$306.00K | -$472.00K | -$737.00K | -$884.00K | -$710.00K | -$805.00K | -$1.03M | -$976.00K | -$1.08M | – |
| Therapeutics Segment | – | – | – | -$12.44M | -$13.17M | -$12.11M | -$94.84M | -$5.01M | -$8.32M | -$12.17M | $4.07M | -$24.58M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licensing | $1.27M | $1.46M | $795.00K | $2.81M | $1.34M | $1.01M | $8.60M | $3.70M | $2.14M | $1.74M | $17.00M | $8.58M | 78.1% | -4.6% |
| Contract research | $356.00K | $537.00K | $500.00K | $485.00K | $442.00K | $445.00K | $615.00K | $645.00K | $625.00K | $657.00K | $566.00K | $705.00K | 21.9% | -19.5% |
By region
From the segment and revenue-disaggregation notes of Aclaris Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.